Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:11:41.599Z.
Calculation as of: 2026-10-06T21:11:41.599Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$3.06B
EV/EBITDA Ratio
N/A
TTM Avg
116.71x
3Y Avg
116.71x
5Y Avg
116.71x
Market Cap
$2.99B
EV/EBITDA Ratio
82.57x
TTM Avg
355.62x
3Y Avg
355.62x
5Y Avg
355.62x
Market Cap
$3.12B
EV/EBITDA Ratio
N/A
TTM Avg
9.21x
3Y Avg
9.21x
5Y Avg
9.21x
Market Cap
$3.19B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.77B
EV/EBITDA Ratio
26.85x
TTM Avg
35.89x
3Y Avg
85.56x
5Y Avg
85.56x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 116.71x | 116.71x | 116.71x |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 82.57x | 355.62x | 355.62x | 355.62x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 9.21x | 9.21x | 9.21x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 26.85x | 35.89x | 85.56x | 85.56x |
| CareDx, Inc (CDNA)vs › | $3.30B | 189.34x | 115.31x | 72.49x | 72.49x |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 75.80x | 85.01x | 85.01x | 85.01x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
